---
document_datetime: 2025-07-17 18:46:15
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nimvastid-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nimvastid-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.9512675
conversion_datetime: 2025-12-22 17:14:20.224028
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nimvastid

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc.Article61(3)-Accepted | 15/07/2025                          |                                          | PL                              |           |

1Notifications areissuedfortypeIvariations andArticle61(3)notifications(unlesspartofagroupincludinga typeIIvariationorextensionapplicationoraworksharingapplication).Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),Annex II,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annex II, labelling,package leaflet).The CDisissuedwithintwomonthsof theopinionforvariationsfallingunderthescopeofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000284684                         | Update of the product information to align the ADRslisted in sections'4.Possible side effects'ofthepackageleafletwithsection 4.8 of the SmPC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |             |                                                                                                                                                                                                                                                |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000253876    | C.I.2 Change(s)in theSummary ofProduct Characteristics,LabellingorPackageLeaflet ofageneric/hybrid/biosimilarmedicinal productsfollowingassessmentofthesame changeforthereferenceproduct-C.I.2.a Implementationofchange(s)forwhichno new additional data is required to be submittedby theMAH-Accepted C.1.2.a(IB)-To update section 4.8 of the SmPCandsection4ofthePackageLeaflet toaddtheadversereactionPleurothotonus (Pisasyndrome)withafrequency'not known\"undertheSocNervoussystem disorders, following approval of the same changein thereferenceproduct. Furthermore,theMarketing Authorisation Holder has taken the opportunity to update thelistoflocalrepresentativesand implementeditorialchangesinDA,CS,EL, andHUto correcttypographicalerrors and alignwiththereferenceproduct annexes. | 26/03/2025 |     | SmPC and PL | Toupdatesection4.8of theSmPC andsection4of thePackageLeaflettoaddthe adversereaction Pleurothotonus(Pisasyndrome)withafrequency 'notknown\"under theSocNervoussystem disorders, following approval of the same change in the reference product. |
| Variation type IA_IN / EMA/VR/0000177024 | B.I.a.1Changeinthemanufacturerofa starting material/reagent/intermediate used in themanufacturingprocessoftheactive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 08/05/2024 | N/A |             |                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| substanceorchangeinthemanufacturer (including where relevant quality control testingsites)oftheactivesubstance,where noPh.Eur.Certificate ofSuitabilityispart of the approved dossier -B.I.a.1.a The proposed manufacturer is part of the same pharmaceuticalgroupasthecurrently approved manufacturer- Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|